A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Condition:   Crohn's Disease Interventions:   Drug: upadacitinib;   Other: Matching placebo for upadacitinib Sponsor:   AbbVie Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials